|Dr. Gerald McMahon||Pres, CEO & Director||832.05k||N/A||1955|
|Ms. Georgia L. Erbez||Chief Financial Officer||554.55k||N/A||1967|
|Dr. Natalie R. Sacks||Chief Medical Offer||633.35k||N/A||1965|
|Dr. Holger Wesche Ph.D.||Chief Scientific Officer||N/A||N/A||1968|
|Ms. Rachael Lester||VP of Corp. Devel.||N/A||N/A||N/A|
|Dr. Susan Dana Jones Ph.D.||Sr. VP of Product Devel.||N/A||N/A||N/A|
|Dr. Che-Leung Law Ph.D.||Sr. VP of Translational Medicine||N/A||N/A||N/A|
|Mr. Christopher Whitmore||VP of Fin. & Sec.||N/A||N/A||N/A|
Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company, engages in the development of a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases in the United States. The company's lead tri-specific t-cell activating construct (TriTAC) product candidate is HPN424, which is in Phase I/IIa clinical trials for the treatment of metastatic castration-resistant prostate cancer. It is also developing HPN536, which is in Phase I/IIa clinical trials for the treatment of ovarian cancer and other mesothelin-expressing tumors; HPN217 that is in Phase I/II clinical trials for the treatment of multiple myeloma; and HPN328, a product candidate in Phase I/II clinical trials for the treatment of small cell lung cancer and other Delta-like canonical Notch ligand 3-expressing tumors. The company has a discovery collaboration and license agreement with AbbVie Biotechnology Ltd. to develop and commercialize products that incorporate our proprietary TriTAC platform technology together with soluble T cell receptors. Harpoon Therapeutics, Inc. was founded in 2015 and is headquartered in South San Francisco, California.
Harpoon Therapeutics, Inc.’s ISS Governance QualityScore as of June 1, 2021 is 7. The pillar scores are Audit: 3; Board: 7; Shareholder Rights: 8; Compensation: 8.